TABLE OF CONTENTS

Chapter 1 Introduction

• 1.1 Executive Summary
• 1.2 Market Definition
• 1.3 Market Scope

Chapter 2 Research Methodology

• 2.1 Primary Research
• 2.2 Research Methodology
• 2.3 Assumptions & Exclusions
• 2.4 Secondary Data Sources

Chapter 3 Market Overview

• 3.1 Report Segmentation & Scope
• 3.2 Key Market Trends
  • 3.2.1 Drivers
  • 3.2.2 Restraints
  • 3.2.3 Opportunities
• 3.3 Porter’s Five Forces Analysis
• 3.4 Market Share Analysis

Chapter 4 Global Pulmonary Arterial Hypertension Market by Drug Class: Market Size and Forecast, 2018 – 2026

• 4.1 Introduction
  • 4.1.1 Market Size and Forecast
• 4.2 Endothelin Receptor Antagonists (ERAs)
  • 4.2.1 Market Size and Forecast
• 4.3 Prostacyclin and Prostacyclin Analogs
  • 4.3.1 Market Size and Forecast
• 4.4 Phosphodiesterase-5 (PDE-5) Inhibitors
  • 4.4.1 Market Size and Forecast
• 4.5 Soluble Guanylate Cyclase (sGC) Stimulators
  • 4.5.1 Market Size and Forecast

Chapter 5 Global Pulmonary Arterial Hypertension Market by Application: Market Size and Forecast, 2018 – 2026

• 5.1 Introduction
  • 5.1.1 Market Size and Forecast
• 5.2 Hospitals
  • 5.2.1 Market Size and Forecast
• 5.3 Clinics
  • 5.3.1 Market Size and Forecast
• 5.4 Other Applications
  • 5.4.1 Market Size and Forecast

Chapter 6 Global Pulmonary Arterial Hypertension Market by Geography: Market Size and Forecast, 2018 – 2026

• 6.1 Introduction
  • 6.1.1 Market Size and Forecast
• 6.2 North America
  • 6.2.1 North America Market Size & Forecast, By Country
  • 6.2.2 North America Market Size & Forecast, By Drug Class
  • 6.2.3 North America Market Size & Forecast, By Application
  • 6.2.4 The U.S.
    • 6.2.4.1 Market Size and Forecast
  • 6.2.5 Canada
    • 6.2.5.1 Market Size and Forecast
  • 6.2.6 Mexico
    • 6.2.6.1 Market Size and Forecast
• 6.3 Europe
  • 6.3.1 Europe Market Size and Forecast, By Country
  • 6.3.2 Europe Market Size and Forecast, By Drug Class
  • 6.3.3 Europe Market Size and Forecast, By Application
  • 6.3.4 UK
    • 6.3.4.1 Market Size and Forecast
  • 6.3.5 Germany
    • 6.3.5.1 Market Size and Forecast
  • 6.3.6 France
    • 6.3.6.1 Market Size and Forecast
  • 6.3.7 Italy
    • 6.3.7.1 Market Size and Forecast
  • 6.3.8 Spain
    • 6.3.8.1 Market Size and Forecast
  • 6.3.9 Rest of Europe
    • 6.3.9.1 Market Size and Forecast
• 6.4 Asia-Pacific
  • 6.4.1 Asia-Pacific Market Size and Forecast, By Country
  • 6.4.2 Asia-Pacific Market Size and Forecast, By Drug Class
  • 6.4.3 Asia-Pacific Market Size and Forecast, By Application
  • 6.4.4 India
    • 6.4.4.1 Market Size and Forecast
  • 6.4.5 China
    • 6.4.5.1 Market Size and Forecast
  • 6.4.6 Australia
    • 6.4.6.1 Market Size and Forecast
  • 6.4.7 Japan
    • 6.4.7.1 Market Size and Forecast
  • 6.4.8 South Korea
    • 6.4.8.1 Market Size and Forecast
  • 6.4.9 Rest of Asia-Pacific
    • 6.4.9.1 Market Size and Forecast
• 6.5 South America
  • 6.5.1 South America Market Size and Forecast, By Country
  • 6.5.2 South America Market Size and Forecast, By Drug Class
  • 6.5.3 South America Market Size and Forecast, By Application
  • 6.5.4 Brazil
    • 6.5.4.1 Market Size and Forecast
  • 6.5.5 Rest of South America
    • 6.5.5.1 Market Size and Forecast
• 6.6 RoW
  • 6.6.1 RoW Market Size and Forecast, By Country
  • 6.6.2 RoW Market Size and Forecast, By Drug Class
  • 6.6.3 RoW Market Size and Forecast, By Application
  • 6.6.4 RoW Market Size and Forecast, By End-User
  • 6.6.5 Middle East
    • 6.6.5.1 Market Size and Forecast
  • 6.6.6 Africa
    • 6.6.6.1 Market Size and Forecast

  Chapter 7 Company Profiles

  • 7.1 Actelion Pharmaceuticals, Ltd.
  • 7.2 Bayer HealthCare
  • 7.3 Gilead Sciences, Inc.
  • 7.4 GlaxoSmithKline Plc.
  • 7.5 Novartis International AG
  • 7.6 Pfizer, Inc.

“Pulmonary Arterial Hypertension Market” 2018-2026 report is a professional study on the current state of the market that focuses on the major drivers, challenges, opportunities for the leading players. The research report also offers a granular analysis of various definitions, and classification of the industry, applications of the industry, regional breakdown, opportunities, challenges, and chain structure.

About Pulmonary Arterial Hypertension Market

The Global Pulmonary Arterial Hypertension market is expected to reach approximately $8.4 billion by 2026, with a projected CAGR of 4.7% during the forecast period. Pulmonary arterial hypertension is a progressive disorder in which blood pressure rises in the pulmonary artery, vein, or capillaries that may lead to shortness of breath, dizziness, and fainting among others. Increasing prevalence of PAH disorder owing to rising risk factors such as sedentary lifestyle, consumption of tobacco and alcohol, smoking, and other idiopathic conditions propels the growth of the global pulmonary arterial hypertension market. Various breakthrough therapies for treatment of pulmonary arterial hypertension, government support for the development of orphan drugs, and increasing geriatric population are other major growth stimulants for the Europe carpet market.

Market Summary:

The Pulmonary Arterial Hypertension market is a comprehensive report which offers a meticulous overview of the market share, size, trends, demand, product analysis, application analysis, regional outlook, competitive strategies, forecasts, and strategies impacting the Pulmonary Arterial Hypertension Industry. The report includes a detailed analysis of the market competitive landscape, with the help of detailed business profiles, SWOT analysis, project feasibility analysis, and several other details about the key companies operating in the market.

The study on the worldwide Pulmonary Arterial Hypertension market strives to offer substantial and profound insights into the current market scenario and the developing growth dynamics. Moreover, the report also provides the market players along with the new contenders a complete view of the market landscape. The inclusive research will enable the well-established as well as the entry-level players to establish their business strategies and accomplish their short-term and long-term goals.

Scope and Segmentation of the Report

The segment analysis is one of the significant sections of this report. Our expert analyst has categorized the market into product type, application/end-user, and geography. All the segments are analyzed based on their market share, growth rate, and growth potential. In the geographical classification, the report highlights the regional markets having high growth potential. This thorough evaluation of the segments would help the players to focus on revenue-generating areas of the Pulmonary Arterial Hypertension market.

Based on Type

By Drug Class
Prostacyclin and Prostacyclin Analogs
Endothelin Receptor Antagonists (ERAs)
Phosphodiesterase 5 (PDE-5) Inhibitors
Soluble Guanylate Cyclase (sGC) Stimulators

Based on Application

Hospitals
Clinics
Others

Regional Analysis

Our analysts are experts in covering all types of geographical markets from developing to mature ones. You can expect a comprehensive research analysis of key regional and country-level markets such as Europe, North America, South America, Asia-Pacific, and the Middle East & Africa. With accurate statistical patterns and regional classification, our domain experts provide you one of the most detailed and easily understandable regional analyses of the Pulmonary Arterial Hypertension market.

Competitive Landscape:

The research report also studied the key players operating in the Pulmonary Arterial Hypertension market. It has evaluated and explained the research & development stages of these companies, their financial performances, and their expansion plans for the coming years. Moreover, the research report also includes the list of planned initiatives that clearly explain the accomplishments of the companies in the recent past.

Company Coverage (Sales Revenue, Price, Gross Margin, Main Products, etc.):

Bayer HealthCare
Actelion Pharmaceuticals Ltd.
Novartis International AG
Gilead Sciences Inc.
GlaxoSmithKline plc
United Therapeutics Corporation
Pfizer Inc.

Research Methodology

The research methodology of the market is based on both primary as well as secondary research data sources. It compels different factors affecting the Pulmonary Arterial Hypertension industry such as historical data and market trends, different policies of the government, market environment, market risk factors, market restraints, technological advancements, forthcoming innovations, and obstacles in the industry.

The content of the study subjects includes a total of 8 chapters:

Chapter 1, describe the Pulmonary Arterial Hypertension market report’s – executive summary, market definition, and market scope. Moreover, the report helps in picking up the crucial information about the said market.

Chapter 2, defines the Research Methodology including primary research, assumptions & exclusions, and secondary data sources. The report follows the simultaneous top-down and bottom approach to provide you the accurate market sizing.

Chapter 3, explains the report segmentation & scope, key market trends (drivers, restraints, and opportunities), along with Porter’s five forces analysis and market share analysis

Chapter 4: It helps in understanding the key product segments and their future of the Pulmonary Arterial Hypertension Market. It provides strategic recommendations in key business segments based on the market estimations.

Chapters 5, and 6 to segment the sales by type and application/end-user, with sales market share and growth rate by type, application/end-user, from 2018 to 2016. Our team of Analysts and experts dedicatedly put their effort to provide you the best possible and accurate segmentation data and analysis.

Chapter 7, describes the regional segmentation based on the country level for the forecast period 2018 – 2026. The research report not only provide the market data of the five geographies but also provide the qualitative as well we qualitative information on country level bifurcation.

Chapter 8, to profile the top manufacturers of Pulmonary Arterial Hypertension, with price, sales, revenue and market share of Pulmonary Arterial Hypertension in 2016, 2017, and 2018. Players are expected to sign acquisition and collaboration deals to expand their products and services portfolio. Such strategic agreements could help them to improve their client base in other countries and gain a competitive advantage